The antinociceptive effect of systemic administration of a combination of low-dose tramadol and dexmedetomidine in a rat model of bone cancer pain

2014 ◽  
Vol 31 (1) ◽  
pp. 30-34 ◽  
Author(s):  
Xiaomin Yuan ◽  
Jingxiang Wu ◽  
Qiong Wang ◽  
Meiying Xu
Keyword(s):  
Cancer Pain ◽  
Rat Model ◽  
Low Dose ◽  
Antinociceptive Effect ◽  
Bone Cancer ◽  
Systemic Administration ◽  
Bone Cancer Pain

scholarly journals Preconditioning with hydrogen sulfide prevents bone cancer pain in rats through a proliferator-activated receptor gamma/p38/Jun N-terminal kinase pathway

2017 ◽  
Vol 243 (1) ◽  
pp. 57-65 ◽  
Author(s):  
Li Zhuang ◽  
Ke Li ◽  
Gaowei Wang ◽  
Tao Shou ◽  
Chunlin Gao ◽  
...  
Keyword(s):  
Spinal Cord ◽  
Cancer Pain ◽  
Rat Model ◽  
Mechanical Allodynia ◽  
Antinociceptive Effect ◽  
Thermal Hyperalgesia ◽  
Bone Cancer ◽  
Bone Cancer Pain ◽  
Kinase Pathway

Bone cancer pain (BCP) is a severe type of hyperpathic pain occurring with primary bone tumors or advanced cancers which metastasize to bones. BCP can detrimentally reduce quality of life and presents a challenge to modern medicine. Studies have shown that exogenous H2S may act as a neuroprotectant to protect against some diseases in central nervous system. The preset study aimed to investigate the antinociceptive effect of H2S in BCP. We first measured the changes of serum H2S in patients with BCP and analyzed the relationship between them, then investigated the effect of H2S preconditioning on BCP, and explored the mechanism in rat model. Our results revealed that serum H2S level was negatively correlated with pain scores. In the rat model of BCP, preconditioning with H2S significantly reduced BCP, demonstrated by the decrease of thermal hyperalgesia and mechanical allodynia. The mechanism of H2S preconditioning may involve microglia deactivation and inflammation inhibition in the spinal cord, in which the proliferator-activated receptor gamma/p38/Jun N-terminal kinase pathway is activated. Impact statement Bone cancer pain (BCP) significantly decreases the life quality of patients or their life expectancy and causes a severe health burden to the society. However, as the exact mechanism of BCP is still poorly understood, no effective treatment has been developed yet. There are some pain medicines now, but they have some inevitable side effects. Additional therapeutic strategies are urgently needed. First, we revealed that preconditioning with H2S significantly reduced BCP, demonstrated by the decrease of thermal hyperalgesia and mechanical allodynia. Second, the mechanism of H2S preconditioning was elucidated. It may involve microglia deactivation and inflammation inhibition in the spinal cord, in which the proliferator-activated receptor gamma/p38/Jun N-terminal kinase pathway is activated. This novel finding may significantly help us to understand the difference between the roles of endogenous H2S and exogenous H2S in the development of BCP and present us a new strategy of pain management.

scholarly journals Antinociceptive Effect of Intrathecal Microencapsulated Human Pheochromocytoma Cell in a Rat Model of Bone Cancer Pain

2014 ◽  
Vol 15 (7) ◽  
pp. 12135-12148 ◽  
Author(s):  
Xiao Li ◽  
Guoqi Li ◽  
Shaoling Wu ◽  
Baiyu Zhang ◽  
Qing Wan ◽  
...  
Keyword(s):  
Cancer Pain ◽  
Rat Model ◽  
Antinociceptive Effect ◽  
Bone Cancer ◽  
Bone Cancer Pain ◽  
Pheochromocytoma Cell

Activation of spinal microglia and astrocytes in a rat model of bone cancer pain

2009 ◽  
Vol 65 ◽  
pp. S178
Author(s):  
Yan-Qing Wang ◽  
Qi-Liang Mao-Ying ◽  
Xiao-Wei Wang ◽  
Gen-Cheng Wu
Keyword(s):  
Cancer Pain ◽  
Rat Model ◽  
Bone Cancer ◽  
Bone Cancer Pain

Protease-Activated Receptor 2 Antagonist Potentiates Analgesic Effects of Systemic Morphine in a Rat Model of Bone Cancer Pain

2015 ◽  
Vol 40 (2) ◽  
pp. 158-165 ◽  
Author(s):  
Yanju Bao ◽  
Wei Hou ◽  
Liping Yang ◽  
Xiangying Kong ◽  
Maobo Du ◽  
...  
Keyword(s):  
Cancer Pain ◽  
Rat Model ◽  
Bone Cancer ◽  
Bone Cancer Pain ◽  
Analgesic Effects ◽  
Protease Activated Receptor 2

scholarly journals circStrn3 is involved in bone cancer pain regulation in a rat model

2020 ◽  
Vol 52 (5) ◽  
pp. 495-505
Author(s):  
Yiwen Zhang ◽  
Xiaoxia Zhang ◽  
Zumin Xing ◽  
Shuyi Tang ◽  
Hanwen Chen ◽  
...  
Keyword(s):  
Cancer Pain ◽  
Rat Model ◽  
Molecular Mechanisms ◽  
Bone Cancer ◽  
Test Body ◽  
Differentially Expressed ◽  
Bone Cancer Pain ◽  
Biological Regulation ◽  
Cellular Processes ◽  
Simplex Infection

Abstract Bone cancer pain (BCP) is a common chronic pain that is caused by a primary or metastatic bone tumor. More detailed molecular mechanisms of BCP are warranted. In this study, we established a BCP rat model. The von Frey hair test, body weight, and hematoxylin and eosin staining were employed. We screened differentially expressed circRNAs (DECs) between the BCP group and sham group. The results revealed that 850 DECs were significantly up-regulated and 644 DECs were significantly down-regulated in the BCP group. Furthermore, we identified 1177 differentially expressed genes (DEGs) significantly up-regulated and 565 DEGs significantly down-regulated in the BCP group. Gene Ontology annotation of all 1742 DEGs revealed that biological regulation of metabolic processes, cellular processes, and binding were the top enriched terms. For Kyoto Encyclopedia of Genes and Genomes analysis, phagosome, HTLV-I infection, proteoglycans in cancer, and herpes simplex infection were significantly enriched in this study. In addition, we identified four selected circRNAs, chr6:72418120|72430205, chr20:7561057|7573740, chr18:69943105|69944476, and chr5:167516581|167558250, by quantitative real time PCR. chr6:72418120|72430205 (circStrn3) was selected for further study based on expression level and the circRNA–miRNA–mRNA network table. Western blot analysis suggested that knockdown of circStrn3 could effectively induce Walker 256 cell apoptosis. In summary, our study provided a more in-depth understanding of the molecular mechanisms of BCP.

scholarly journals The antinociceptive effect of resveratrol in bone cancer pain is inhibited by the Silent Information Regulator 1 inhibitor selisistat

2018 ◽  
Vol 71 (5) ◽  
pp. 816-825 ◽  
Author(s):  
Sebastian Lux ◽  
Nicolas Lobos ◽  
Carolyne Lespay‐Rebolledo ◽  
Edison Salas‐Huenuleo ◽  
Marcelo J. Kogan ◽  
...  
Keyword(s):  
Cancer Pain ◽  
Antinociceptive Effect ◽  
Bone Cancer ◽  
Bone Cancer Pain ◽  
Silent Information Regulator 1

scholarly journals Antinociceptive Effect of Intrathecal Injection of Genetically Engineered Human Bone Marrow Stem Cells Expressing the Human Proenkephalin Gene in a Rat Model of Bone Cancer Pain

2017 ◽  
Vol 2017 ◽  
pp. 1-11 ◽  
Author(s):  
Yi Sun ◽  
Yuke Tian ◽  
Haifeng Li ◽  
Dengwen Zhang ◽  
Qiang Sun
Keyword(s):  
Stem Cells ◽  
Bone Marrow ◽  
Gene Transfer ◽  
Cancer Pain ◽  
Rat Model ◽  
Bone Cancer ◽  
Genetically Engineered ◽  
Human Bone ◽  
Human Bone Marrow ◽  
Bone Cancer Pain

Background. This study aimed to investigate the use of human bone marrow mesenchymal stem cells (hBMSCs) genetically engineered with the human proenkephalin (hPPE) gene to treat bone cancer pain (BCP) in a rat model.Methods. Primary cultured hBMSCs were passaged and modified with hPPE, and the cell suspensions (6 × 106) were then intrathecally injected into a rat model of BCP. Paw mechanical withdrawal threshold (PMWT) was measured before and after BCP. The effects of hPPE gene transfer on hBMSC bioactivity were analyzed in vitro and in vivo.Results. No changes were observed in the surface phenotypes and differentiation of hBMSCs after gene transfer. The hPPE-hBMSC group showed improved PMWT values on the ipsilateral side of rats with BCP from day 12 postoperatively, and the analgesic effect was reversed by naloxone. The levels of proinflammatory cytokines such as IL-1βand IL-6 were ameliorated, and leucine-enkephalin (L-EK) secretion was augmented, in the hPPE-engineered hBMSC group.Conclusion. The intrathecal administration of BMSCs modified with the hPPE gene can effectively relieve pain caused by bone cancer in rats and might be a potentially therapeutic tool for cancer-related pain in humans.

Spinal glial activation in a new rat model of bone cancer pain produced by prostate cancer cell inoculation of the tibia

Pain ◽  
2005 ◽  
Vol 118 (1) ◽  
pp. 125-136 ◽  
Author(s):  
Rui-Xin Zhang ◽  
Bing Liu ◽  
Linbo Wang ◽  
Ke Ren ◽  
Jian-Tian Qiao ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cancer Pain ◽  
Cancer Cell ◽  
Rat Model ◽  
Prostate Cancer Cell ◽  
Bone Cancer ◽  
Glial Activation ◽  
Bone Cancer Pain ◽  
Cell Inoculation

scholarly journals Behavioral, Medical Imaging and Histopathological Features of a New Rat Model of Bone Cancer Pain

PLoS ONE ◽  
2010 ◽  
Vol 5 (10) ◽  
pp. e13774 ◽  
Author(s):  
Louis Doré-Savard ◽  
Valérie Otis ◽  
Karine Belleville ◽  
Myriam Lemire ◽  
Mélanie Archambault ◽  
...  
Keyword(s):  
Medical Imaging ◽  
Cancer Pain ◽  
Rat Model ◽  
Bone Cancer ◽  
Bone Cancer Pain ◽  
Histopathological Features

S186 INVOLVEMENT OF KAPPA AND DELTA OPIOID RECEPTORS IN THE ANTINOCICEPTIVE EFFECT OF CROTALPHINE IN A BONE CANCER PAIN MODEL

2011 ◽  
Vol 5 (1) ◽  
pp. 221
Author(s):  
V.P. Gutierrez ◽  
P. Brigatte ◽  
V.O. Zambelli ◽  
G. Picolo ◽  
J.S.D. Carvalho ◽  
...  
Keyword(s):  
Cancer Pain ◽  
Opioid Receptors ◽  
Antinociceptive Effect ◽  
Bone Cancer ◽  
Bone Cancer Pain ◽  
Pain Model ◽  
Delta Opioid Receptors
Sign in / Sign up

Export Citation Format

Share Document